pembrolizumab,mrna-4157
merck,moderna
['key,note,42', 'key,note,57', 'mrna4157', 'keynote,942', 'pembro']
#aacr23 plenary #clinicaltrials session- keynote942 randomized phase ii trial (n=157)-mrna4157- a personalized neoantigen mrna vaccine agent combined with pembrolizumab significantly improved recurrence-free survival (rfs) vs. pembrolizumab alone (44% reduced risk of recurrence 
GU Oncology+Phase I Director @AdventHealth Cancer Institute, Professor @ucf Orlando, Editor @practiceupdate, #ASCO, #ESMO, Following/RT≠ endorsement, Views mine